U.S. markets closed

Illumina, Inc. (ILMN)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
137.32-1.36 (-0.98%)
Al cierre: 04:00PM EDT
137.50 +0.18 (+0.13%)
Fuera de horario: 07:24PM EDT

Illumina, Inc.

5200 Illumina Way
San Diego, CA 92122
United States
858 202 4500
https://www.illumina.com

Sector(es)Healthcare
IndustriaDiagnostics & Research
Empleados a tiempo completo10,590

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Joydeep Goswami M.B.A., Ph.D.CFO, Chief Strategy & Corporate Development Officer787.3kN/D1971
Mr. Jacob Thaysen Ph.D.CEO & DirectorN/DN/D1975
Stephanie CamposPresidentN/DN/DN/D
Mr. Kevin Carl PegelsChief of Global OperationsN/DN/D1967
Mr. Scott EricksenVP & Chief Accounting OfficerN/DN/D1972
Dr. Steven Barnard Ph.D.Chief Technology OfficerN/DN/DN/D
Ms. Carissa L. RollinsChief Information OfficerN/DN/D1971
Ms. Sallilyn SchwartzVice President of Investor RelationsN/DN/DN/D
Mr. Charles E. Dadswell Esq.Senior VP & General Counsel1.06MN/D1959
Ms. Kathryne Gambrell ReevesChief Marketing OfficerN/DN/D1969
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Illumina, Inc. a partir del 1 de marzo de 2024 es 10. Las puntuaciones principales son Auditoría: 9; Junta: 8; Derechos del accionista: 7; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.